BMS-214662 mesylate is a chemical compound that belongs to the class of small molecule inhibitors, specifically designed to target certain protein kinases. It is primarily recognized for its role in cancer research, particularly in the context of inhibiting the activity of the protein kinase AKT, which is involved in various cellular processes such as metabolism, proliferation, and survival. The mesylate salt form enhances its solubility and stability, making it more suitable for pharmaceutical applications. BMS-214662 exhibits characteristics typical of kinase inhibitors, including the ability to interfere with signaling pathways that promote tumor growth. Its chemical structure includes functional groups that facilitate binding to the target enzyme, thereby inhibiting its activity. In preclinical studies, BMS-214662 has shown potential efficacy in various cancer models, highlighting its importance in the development of targeted cancer therapies. However, further research is necessary to fully understand its pharmacokinetics, safety profile, and therapeutic potential in clinical settings.

BMS-214662 mesylate

474010-58-7: BMS-214662 mesylate is a chemical compound that belongs to the class of small molecule inhibitors, specifically designed to target certain protein kinases. It is primarily recognized for its role in cancer research, particularly in the context of inhibiting the activity of the protein kinase AKT, which is involved in various cellular processes such as metabolism, proliferation, and survival. The mesylate salt form enhances its solubility and stability, making it more suitable for pharmaceutical applications. BMS-214662 exhibits characteristics typical of kinase inhibitors, including the ability to interfere with signaling pathways that promote tumor growth. Its chemical structure includes functional groups that facilitate binding to the target enzyme, thereby inhibiting its activity. In preclinical studies, BMS-214662 has shown potential efficacy in various cancer models, highlighting its importance in the development of targeted cancer therapies. However, further research is necessary to fully understand its pharmacokinetics, safety profile, and therapeutic potential in clinical settings.

<p>BMS-214662 mesylate is a potent and selective farnesyl transferase inhibitor with an IC50 of 1.35 nM. It exhibits antitumor activity and is applicable in cancer research.</p>

CAS 474010-58-7

BMS-214662 mesylate

BMS-214662 mesylate

Ref: TM-T204276